{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:20:48Z","timestamp":1773832848875,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jfma.2021.12.012","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:07:16Z","timestamp":1641035236000},"page":"S30-S38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["Trends of medication used in patients with pre-ESKD from 2010 to 2018 in Taiwan"],"prefix":"10.1016","volume":"121","author":[{"given":"Cheng-Jui","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hung","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ju","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Huang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-5661","authenticated-orcid":false,"given":"Pei-Lun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2021.12.012_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000491708","article-title":"Incidence, prevalence, and duration of chronic kidney disease in Taiwan: results from a community-based screening program of 106,094 individuals","volume":"140","author":"Tsai","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.jfma.2021.12.012_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1681\/ASN.2018050531","article-title":"Projecting ESRD incidence and prevalence in the United States through 2030","volume":"30","author":"McCullough","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.12.012_bib3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1046\/j.1523-1755.2000.00945.x","article-title":"Vintage, nutritional status, and survival in haemodialysis patients","volume":"57","author":"Chertow","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.12.012_bib4","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2009.10.009","article-title":"Excerpts from the US renal data System 2009 annual data report","volume":"55","author":"Collins","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2021.12.012_bib5","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1097\/01.ASN.0000019641.41496.1E","article-title":"Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study","volume":"13","author":"Longenecker","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.12.012_bib6","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2021.12.012_bib7","first-page":"S5","article-title":"Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines","volume":"9","author":"Culleton","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.12.012_bib8","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0272-6386(00)70239-3","article-title":"Cardiovascular disease and chronic renal disease: a new paradigm","volume":"35","author":"Sarnak","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2021.12.012_bib9","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","article-title":"Cardiovascular disease in dialysis patients","volume":"33","author":"Cozzolino","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.12.012_bib10","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1093\/ndt\/gfq251","article-title":"Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients","volume":"25","author":"Lin","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.12.012_bib11","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1681\/ASN.2005020192","article-title":"Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease","volume":"16","author":"Stevens","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.12.012_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.06520714","article-title":"Chronic pain and analgesic use in CKD: implications for patient safety","volume":"10","author":"Wu","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.12.012_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2021.12.012_bib15","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1038\/s41598-019-38991-z","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population","volume":"9","author":"Zheng","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2021.12.012_bib16","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4158\/EP-2020-0143","article-title":"Dipeptidyl-peptidase 4 inhibitors did not improve renal endpoints in advanced diabetic kidney disease","volume":"26","author":"Kornelius","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jfma.2021.12.012_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3747\/pdi.2013.00344","article-title":"Metformin in chronic kidney disease: time for a rethink","volume":"34","author":"Heaf","year":"2014","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.jfma.2021.12.012_bib18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jfma.2021.12.012_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the diabesity working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.12.012_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","article-title":"Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk","volume":"19","author":"Giorgino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jfma.2021.12.012_bib21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.12.012_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/heartjnl-2016-310540","article-title":"Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?","volume":"103","author":"Black-Maier","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jfma.2021.12.012_bib23","doi-asserted-by":"crossref","first-page":"e202175","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jfma.2021.12.012_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621005775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621005775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:45:58Z","timestamp":1760539558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621005775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":23,"alternative-id":["S0929664621005775"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.12.012","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends of medication used in patients with pre-ESKD from 2010 to 2018 in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}